Vertex Pharmaceuticals Inc (VRTX)

[surf1944]

7:03AM Vertex Pharm says Phase 3 ILLUMINATE study supports 24-week Telaprevir-based therapy within a response-guided regimen for people with hepatitis C who had not received prior treatment (VRTX) 37.00 : Co announces results from the Phase 3 ILLUMINATE study, which was designed to evaluate whether there was any benefit to extending therapy from 24 to 48 weeks in people whose hepatitis C virus was undetectable at weeks 4 and 12 of treatment. The safety and tolerability profile of the telaprevir-based regimen was consistent with results reported previously from the pivotal Phase 3 ADVANCE study.